论文部分内容阅读
在IFN-αb(商品名IntronA)被批准用于慢性非甲非乙肝炎(也叫丙型肝炎)后仅几个月,就被批准用于慢性乙型肝炎。在涉及200多名患者的几项研究中,本品对40％～50％的患者有效。在2～6个月的随访中未见
It was approved for chronic hepatitis B only a few months after IFN-αb (trade name IntronA) was approved for chronic non-A non-B hepatitis (also called Hepatitis C). In several studies involving more than 200 patients, this product is effective in 40% to 50% of patients. No follow-up in 2 to 6 months